These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28870508)

  • 1. Inappropriate Dexamethasone Use by a Trekker in Nepal: A Case Report.
    Haslam NR; Garth R; Kelly N
    Wilderness Environ Med; 2017 Dec; 28(4):318-321. PubMed ID: 28870508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding of Altitude Illness and Use of Pharmacotherapy Among Trekkers and Porters in the Annapurna Region of Nepal.
    Havryliuk T; Acharya B; Caruso E; Cushing T
    High Alt Med Biol; 2015 Sep; 16(3):236-43. PubMed ID: 26244262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of changing trekker demographics on travel health in the Annapurna region.
    Kc B; Heydon S; Norris P
    Public Health; 2019 Mar; 168():157-163. PubMed ID: 30415826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of patients with severe altitude illness in Nepal.
    Leshem E; Pandey P; Shlim DR; Hiramatsu K; Sidi Y; Schwartz E
    J Travel Med; 2008; 15(5):315-22. PubMed ID: 19006504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the workload of the two high altitude aid posts in the Nepal Himalayas.
    Basnyat B; Savard GK; Zafren K
    J Travel Med; 1999 Dec; 6(4):217-22. PubMed ID: 10575168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Risk Profiles and Pre-Existing Health Conditions of Trekkers in the Solu-Khumbu Region, Nepal.
    Haunolder M; Apel C; Bertsch D; Cerfontaine C; van der Giet M; van der Giet S; Grass M; Heussen NM; Hundt N; Jäger J; Kühn C; Musiol S; Timmermann L; Wernitz K; Gieseler U; Morrison A; Schöffl V; Küpper T
    Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Older age, chronic medical conditions and polypharmacy in Himalayan trekkers in Nepal: an epidemiologic survey and case series.
    Keyes LE; Mather L; Duke C; Regmi N; Phelan B; Pant S; Starling J; McElwee M; Cole D; McConnell T; Paudel P; Sallade TD; Sheets A; Twillman D; Young DS; Basnyat B
    J Travel Med; 2016 Jun; 23(6):. PubMed ID: 27503853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute mountain sickness (AMS) in a Nepali pilgrim after rapid ascent to a sacred lake (4380 m) in the Himalayas.
    Thapa SS; Basnyat B
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inpatient treatment of trekkers and Nepalese workers in the high-altitude environment of Mt. Everest Region 1996-2011: A retrospective analysis.
    Kühn C; Apel C; Bertsch D; Grass M; Gschwandtl C; Hundt N; Müller-Ost M; Risse J; Schmitz S; Sherpa K; Timmermann L; van der Giet M; van der Giet S; Wernitz K; Morrison A; Küpper T
    Travel Med Infect Dis; 2019; 31():101356. PubMed ID: 30502547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication Use Among Mount Everest Climbers: Practice and Attitudes.
    Luks AM; Grissom C; Freer L; Hackett P
    High Alt Med Biol; 2016 Dec; 17(4):315-322. PubMed ID: 27763796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute mountain sickness prophylaxis: knowledge, attitudes, & behaviours in the Everest region of Nepal.
    Kilner T; Mukerji S
    Travel Med Infect Dis; 2010 Nov; 8(6):395-400. PubMed ID: 21112541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up.
    Gaillard S; Dellasanta P; Loutan L; Kayser B
    High Alt Med Biol; 2004; 5(4):410-9. PubMed ID: 15671630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.
    Basnyat B; Gertsch JH; Holck PS; Johnson EW; Luks AM; Donham BP; Fleischman RJ; Gowder DW; Hawksworth JS; Jensen BT; Kleiman RJ; Loveridge AH; Lundeen EB; Newman SL; Noboa JA; Miegs DP; O'Beirne KA; Philpot KB; Schultz MN; Valente MC; Wiebers MR; Swenson ER
    High Alt Med Biol; 2006; 7(1):17-27. PubMed ID: 16544963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the incidence and understanding of altitude illness between porters and trekkers in the Solu Khumbu Region of Nepal.
    Newcomb L; Sherpa C; Nickol A; Windsor J
    Wilderness Environ Med; 2011 Sep; 22(3):197-201. PubMed ID: 21962045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications of steroid use on Mt. Everest.
    Subedi BH; Pokharel J; Goodman TL; Amatya S; Freer L; Banskota N; Johnson E; Basnyat B
    Wilderness Environ Med; 2010 Dec; 21(4):345-8. PubMed ID: 21168788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Incidence, prevention and therapy of acute mountain sickness].
    Oelz O
    Schweiz Med Wochenschr; 1982 Apr; 112(14):492-5. PubMed ID: 7079685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical problems of porters and trekkers in the Nepal Himalaya.
    Basnyat B; Litch JA
    Wilderness Environ Med; 1997 May; 8(2):78-81. PubMed ID: 11990146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The causes of death among trekkers in Nepal.
    Shlim DR; Gallie J
    Int J Sports Med; 1992 Oct; 13 Suppl 1():S74-6. PubMed ID: 1483800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mountaineering and altitude sickness].
    Maggiorini M
    Ther Umsch; 2001 Jun; 58(6):387-93. PubMed ID: 11441701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High altitude pulmonary edema: the importance of early diagnosis].
    Pratali L; Cavana M; Giardini G
    Recenti Prog Med; 2010 May; 101(5):212-8. PubMed ID: 20590018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.